However , in non-high-risk patients , the restricted mean survival time did not differ significantly between the two treatment groups ( @ months -LSB- @ % CI @-@ -RSB- ) in the standard chemotherapy group vs @ months -LSB- @-@ -RSB- in the bevacizumab group ; p = @ ) .